Rapid generation of combined CMV-specific CD4+ and CD8 + T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants

Blood

Volumn 103, Issue 9, 2004, Pages 3565-3572

  Rauser, Georg ^b   Einsele, Hermann ^b   Sinzger, Christian ^b   Wernet, Dorothee ^b   Kuntz, Gabriele ^b   Assenmacher, Mario ^b   Campbell, John D M ^b   Topp, Max S ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; CYTOMEGALOVIRUS ANTIGEN PP65; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ARTICLE; BLOOD AUTOTRANSFUSION; BLOOD COMPONENT; CELL ISOLATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOMEGALOVIRUS; DONOR; HUMAN; HUMAN CELL; LEUKAPHERESIS; LYMPHOCYTE TRANSFER; MAJOR HISTOCOMPATIBILITY COMPLEX; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; PRIORITY JOURNAL; RANDOMIZATION; RECIPIENT; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 1942489201     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-09-3056     Document Type: Article

References (36)

1. Boeckh M, Bowden RA, Gooley T, Myerson D, Corey L. Successful modification of a pp65 anti-genemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. Blood. 1999;93:1781-1782.
2. Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood. 1995;86:2815-2820.
3. Ljungman P, Engelhard D, Link H, et al. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group. Clin Infect Dis. 1992;14:831-835.
4. Einsele H, Hebart H, Kauffmann-Schneider C, et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant. 2000;25:757-763.
5. Eckle T, Prix L, Jahn G, et al. Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood. 2000;96:3286-3289.
6. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood. 2002;99:4357-4363.
7. Aversa F, Velardi A, Tabilio A, Reisner Y, Martelli MF. Haploidentical stem cell transplantation in leukemia. Blood Rev. 2001;15:111-119.
8. Zaia JA, Gallez-Hawkins G, Li X, et al. Related articles, infrequent occurrence of natural mutations in the pp65(495-503) epitope sequence presented by the HLAA*0201 allele among human cytomegalovirus isolates. J Virol. 2001;75:2472-2474.
9. Kern F, Bunde T, Faulhaber N, et al. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J Infect Dis. 2002;185:1709-1716
10. Waldrop SL, Pitcher CJ, Peterson DM, Maino VC, Picker LJ. Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J Clin Invest. 1997;99:1739-1750.
11. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T lymphocyte response to cytomegalovirus following human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood. 1991;78:1373-1380.
12. Ljungman P, Lonnqvist B, Wahren B, Ringden O, Gahrton G. Lymphocyte responses after cytomegalovirus infection in bone marrow transplant recipients-a one-year follow-up. Transplantation. 1985;40:515-520.
13. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T-cell clones. Science. 1992;257:238-241.
14. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038-1044.
15. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T-cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 2002;99:3916-3922.
16. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996;2:551-555.
17. Szmania S, Galloway A, Bruorton M, et al. Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers. Blood. 2001;98:505-512.
18. Koehne G, Gallardo HF, Sadelain M, O'Reilly RJ. Rapid selection of antigen-specific T lymphocytes by retroviral transduction. Blood. 2000;96:109-117.
19. Kondo E, Topp MS, Kiem HP, et al. Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells. J Immunol. 2002;169:2164-2171.
20. Kleihauer A, Grigoleit U, Hebart H, et al. Ex vivo generation of human cytomegalovirus-specific cytotoxic T-cells by peptide-pulsed dendritic cells. Br J Haematol. 2001;113:231-239.
21. + T lymphocytes using dendritic cells pulsed with a human leucocyte antigen A*0201-restricted peptide. Br J Haematol. 2001;113:479-482.
22. Peggs K, Verfuerth S, Mackinnon S. Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions. Blood. 2001;97:994-1000.
23. +) T-cells based on cytokine secretion. Eur J Immunol. 1999;29:4053-4059.
24. Becker C, Pohla H, Frankenberger B, et al. Adoptive tumor therapy with T lymphocytes enriched through an IFN-γ capture assay. Nat Med. 2001;7:1159-1162.
25. Bissinger AL, Rauser G, Hebart H, et al. Isolation and expansion of human cytomegalovirus-specific cytotoxic T lymphocytes using interferon-gamma secretion assay. Exp Hematol. 2002;30:1178-1184.
26. Thurner B, Roder C, Dieckmann D, et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods. 1999;223:1-15.
27. + memory effector T-cells reconstitutes antigen-induced IL-2 production. J Exp Med. 2003;198:945-953.
28. Goldrath AW, Bevan MJ. Low-affinity ligands for the TCR drive proliferation of mature CD8+ T cells in lymphopenic hosts. Immunity. 1999;11:183-190.
29. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854.
30. Koehne G, Smith KM, Ferguson TL, et al. Quantitation, selection, and functional characterization of Epstein-Barr virus-specific and alloreactive T cells detected by intracellular interferon-gamma production and growth of cytotoxic precursors. Blood. 2002;99:1730-1740.
31. Khan N, Cobbold M, Keenan R, Moss PA. Comparative analysis of CD8+ T cell responses against human cytomegalovirus proteins pp65 and immediate early 1 shows similarities in precursor frequency, oligoclonality, and phenotype. J Infect Dis. 2002;185:1025-1034.
32. Hebart H, Rauser G, Stevanovic S, et al. A CTL epitope from HCMV IE1 defined by combining prediction of HLA binding and proteasomal processing is the target of dominant immune responses in patients after allogeneic SCT. Exp Hematol. 2003;31:966-973.
33. Gilbert MJ, Riddell SR, Plachter B, Greenberg PD. Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature. 1996;383:720-722.
34. Toro AI, Ossa J. PCR activity of CMV in healthy CMV-seropositive individuals: does latency need redefinition? Res Virol. 1996;147:233-238.
35. Docke WD, Prosch S, Fietze E, et al. Cytomegalovirus reactivation and tumour necrosis factor. Lancet. 1994;343:268-269.
36. Reddehase MJ. Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance. Nat Rev Immunol. 2002;2:831-844.